European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update (Q38661777)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

5 September 2017

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update (English)

1 reference

Europe PubMed Central

5 September 2017

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

14

1 reference

Europe PubMed Central

5 September 2017

0 references

Dennis McGonagle

24

object named as

D McGonagle

0 references

Philip Helliwell

18

object named as

P Helliwell

0 references

Helena Marzo-Ortega

23

object named as

H Marzo-Ortega

0 references

object named as

L Gossec

1

0 references

object named as

S Ramiro

3

0 references

object named as

R Lories

20

0 references

object named as

K Pavelka

27

0 references

19

object named as

T K Kvien

1 reference

Europe PubMed Central

5 September 2017

Gerd-Rüdiger Burmester

13

object named as

G Burmester

1 reference

Europe PubMed Central

5 September 2017

author name string

J S Smolen

2

1 reference

Europe PubMed Central

5 September 2017

M de Wit

4

1 reference

Europe PubMed Central

5 September 2017

M Cutolo

5

1 reference

Europe PubMed Central

5 September 2017

M Dougados

6

1 reference

Europe PubMed Central

5 September 2017

R Landewé

8

1 reference

Europe PubMed Central

5 September 2017

S Oliver

9

1 reference

Europe PubMed Central

5 September 2017

D Aletaha

10

1 reference

Europe PubMed Central

5 September 2017

N Betteridge

11

1 reference

Europe PubMed Central

5 September 2017

J Braun

12

1 reference

Europe PubMed Central

5 September 2017

N Damjanov

15

1 reference

Europe PubMed Central

5 September 2017

O FitzGerald

16

1 reference

Europe PubMed Central

5 September 2017

E Haglund

17

1 reference

Europe PubMed Central

5 September 2017

T Luger

21

1 reference

Europe PubMed Central

5 September 2017

M Maccarone

22

1 reference

Europe PubMed Central

5 September 2017

I B McInnes

25

1 reference

Europe PubMed Central

5 September 2017

I Olivieri

26

1 reference

Europe PubMed Central

5 September 2017

G Schett

28

1 reference

Europe PubMed Central

5 September 2017

J Sieper

29

1 reference

Europe PubMed Central

5 September 2017

F van den Bosch

30

1 reference

Europe PubMed Central

5 September 2017

D J Veale

31

1 reference

Europe PubMed Central

5 September 2017

J Wollenhaupt

32

1 reference

Europe PubMed Central

5 September 2017

A Zink

33

1 reference

Europe PubMed Central

5 September 2017

D van der Heijde

34

1 reference

Europe PubMed Central

5 September 2017

language of work or name

0 references

publication date

7 December 2015

1 reference

Europe PubMed Central

5 September 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

5 September 2017

75

1 reference

Europe PubMed Central

5 September 2017

3

1 reference

Europe PubMed Central

5 September 2017

499-510

1 reference

Europe PubMed Central

5 September 2017

A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Going from evidence to recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Incorporating considerations of resources use into grading recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Recognizing and managing comorbidities in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: a report from the GRAPPA 2013 Annual Meeting.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Predictors for radiological damage in psoriatic arthritis: results from a single centre

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Clinical and radiological damage in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Composite measures in psoriatic arthritis: GRAPPA 2008.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Development of a preliminary composite disease activity index in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Dactylitis in psoriatic arthritis: a marker for disease severity?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Clinical improvement in psoriasis with specific targeting of interleukin-23.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Interleukin-17 inhibition in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Comprehensive treatment of dactylitis in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F))

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treatment recommendations for psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2015-208337

1 reference

Europe PubMed Central

5 September 2017

10.1136/ANNRHEUMDIS-2015-208337

0 references

Dimensions Publication ID

0 references

Microsoft Academic ID

0 references

1 reference

Europe PubMed Central

5 September 2017

2-s2.0-84960126976

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38661777&oldid=1772804345"